We are live on ! Find out more
IAM

Iridian Asset Management Portfolio holdings

AUM $291M
1-Year Est. Return 49.45%
This Fund
S&P 500
This Quarter Est. Return
+31.2%
1 Year Est. Return
+49.45%
3 Year Est. Return
+82.55%
5 Year Est. Return
+101.12%
10 Year Est. Return
+450.66%
AUM
$291M
AUM Growth
+$44.4M
Cap. Flow
-$10.6M
Cap. Flow %
-3.64%
Top 10 Hldgs %
67.2%
Holding
44
New
2
Increased
9
Reduced
27
Closed
3

Top Buys

Rank Stock Value
1
HLF icon
Herbalife
HLF
+$6.29M
2
POST icon
Post Holdings
POST
+$4.18M
3
LPLA icon
LPL Financial
LPLA
+$2.32M
4
AMRZ
Amrize Ltd
AMRZ
+$2.11M
5
PGEN icon
Precigen
PGEN
+$1.9M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$4.24M
2
ACVA icon
ACV Auctions
ACVA
+$3.53M
3
ENR icon
Energizer
ENR
+$2.63M
4
ELV icon
Elevance Health
ELV
+$2.46M
5
FLEX icon
Flex
FLEX
+$2.4M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 34.48%
2 Healthcare 21.06%
3 Consumer Staples 17.48%
4 Technology 12.18%
5 Financials 4.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BKR icon
26
Baker Hughes
BKR
$58.6B
$2.59M 0.89%
46,580
-2,740
-6% -$173K
ICE icon
27
Intercontinental Exchange
ICE
$88.4B
$2.09M 0.72%
16,981
+1,466
+9% +$220K
BALL icon
28
Ball Corp
BALL
$15.9B
$2.07M 0.71%
33,139
-1,937
-6% -$114K
SLB icon
29
SLB Ltd
SLB
$83.2B
$2.04M 0.7%
43,927
-9,023
-17% -$484K
QSR icon
30
Restaurant Brands International
QSR
$26.8B
$1.73M 0.6%
23,890
-5,929
-20% -$451K
TGTX icon
31
TG Therapeutics
TGTX
$8.25B
$1.52M 0.52%
27,689
-47,600
-63% -$1.95M
ENR icon
32
Energizer
ENR
$1.41B
$1.46M 0.5%
67,913
-137,848
-67% -$2.63M
ABVX
33
Abivax
ABVX
$10.4B
$1.22M 0.42%
+9,165
New +$1.04M
RH icon
34
RH
RH
$2.54B
$941K 0.32%
5,714
-353
-6% -$48.7K
FLS icon
35
Flowserve
FLS
$9.46B
$693K 0.24%
+9,348
New +$711K
DBRG icon
36
DigitalBridge
DBRG
$2.98B
$624K 0.21%
39,518
– –
Z icon
37
Zillow
Z
$7.31B
$536K 0.18%
17,013
-1,027
-6% -$39.5K
LH icon
38
Labcorp
LH
$25.3B
$496K 0.17%
1,771
-1,056
-37% -$278K
MOH icon
39
Molina Healthcare
MOH
$10.7B
$353K 0.12%
1,542
-6,288
-80% -$1.14M
BCTX
40
Briacell Therapeutics
BCTX
$31.6M
$211K 0.07%
65,000
– –
BCTXL
41
BriaCell Therapeutics Warrant
BCTXL
$2.46M
$57.9K 0.02%
65,000
– –
CRL icon
42
Charles River Laboratories
CRL
$13.3B
– –
-9,845
Closed -$1.7M
ELTX icon
43
Elicio Therapeutics
ELTX
$53.9M
– –
-30,051
Closed -$321K
YOU icon
44
Clear Secure
YOU
$4.35B
– –
-21,478
Closed -$1.04M
1
2

Similar funds

HMP
HS Management Partners New York $291M AUM 2.11% 1-Year Est. Return
NTIC
Napean Trading & Investment Company Singapore $291M AUM 61.93% 1-Year Est. Return
MPPHD
Maloon Powers Pitre Higgins & Dennehy San Ramon, California $291M AUM
TP
Tranquility Partners Brentwood, Tennessee $291M AUM 19.25% 1-Year Est. Return
ACG
Arch Capital Group Pembroke, Bermuda $291M AUM 0.79% 1-Year Est. Return
PWM
Power Wealth Management Alpharetta, Georgia $291M AUM 11.57% 1-Year Est. Return
AC
AMS Capital Sao Paulo, Brazil $291M AUM 1.37% 1-Year Est. Return
SVWG
Shared Vision Wealth Group Carlsbad, United States $291M AUM 22.01% 1-Year Est. Return

Iridian Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Iridian Asset Management held 44 positions worth $291M, up 18% from $247M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Iridian Asset Management withdrew a net $10.6M in Q2 2026, closing 3 positions and reducing 27 holdings. Its most notable exit was Charles River Laboratories, an estimated $1.7M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 34% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Iridian Asset Management opened a new position in Abivax worth $1.22M.

  • Iridian Asset Management's largest Q2 2026 buy was Abivax: 9,165 shares worth $1.22M.
  • Iridian Asset Management added most to Herbalife in Q2 2026, an estimated $6.29M increase.
  • Iridian Asset Management's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $4.24M.
  • Iridian Asset Management fully exited Charles River Laboratories in Q2 2026, selling an estimated $1.7M.
  • Iridian Asset Management's ten largest holdings make up 67% of its $291M portfolio in Q2 2026.
  • Iridian Asset Management opened 2 new positions and closed 3 in Q2 2026.
  • Iridian Asset Management's portfolio value rose 18% quarter-over-quarter to $291M.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.